首页> 外文期刊>Biochimica et biophysica acta. Molecular basis of disease: BBA >The G protein-coupled P2Y(6) receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis
【24h】

The G protein-coupled P2Y(6) receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis

机译:G蛋白偶联的P2Y(6)受体通过抑制细胞凋亡来促进结肠直肠癌肿瘤瘤

获取原文
获取原文并翻译 | 示例
       

摘要

Colorectal tumors are immersed in an array of tumor-promoting factors including extracellular nucleotides such as uridine 5'-diphosphate (UDP). UDP is the endogenous agonist of the G protein-coupled P2Y(6) receptor (P2Y(6)R), which may contribute to the formation of a tumor-promoting microenvironment by coordinating resistance to apoptosis. Colorectal cancer (CRC) was chemically induced in P2ry(6) knockout (P2ry(6)(-/-)) mice using azoxymethane and dextran sulfate sodium challenges. Mice were euthanatized and their tumor load determined. Fixed tissues were stained for histological and immunohistochemistry analysis. Tumoroids were also prepared from CRC tumors resected from P2ry6(+/+) mice to determine the role of P2Y(6)R in resistance to apoptosis, whereas HT29 carcinoma cells were used to elucidate the signaling mechanism involved in P2Y(6)R anti-apoptotic effect. P2ry(6)(-/-) mice developed a reduced number of colorectal tumors with apparent tumors having smaller volumes. Overall dysplastic score was significantly lower in P2ry(6)(-/-) animals. Stimulation of P2Y(6)R with the selective agonist MRS2693 protected HT-29 cells from TNF alpha-induced apoptosis. This protective effect was mediated by the stabilizing phosphorylation of the X-linked inhibitor of apoptosis protein (XIAP) by AKT. Using CRC-derived tumoroids, P2Y(6)R activation was found to contribute to chemoresistance since addition of the P2Y(6)R agonist MRS2693 significantly prevented the cytotoxic effect of 5-fluorouracil. The present study shows that sustained activation of P2Y(6)R may contribute to intestinal tumorigenesis by blocking the apoptotic process and by contributing to chemoresistance, a substantial concern in the treatment of patients with CRC. These results suggest that P2Y(6)R may represent a prime target for reducing colorectal carcinogenesis.
机译:结直肠肿瘤浸入肿瘤促进因子阵列中,包括细胞外核苷酸如尿苷5'-二磷酸(UDP)。 UDP是G蛋白偶联P2Y(6)受体的内源激动剂(P2Y(6)R),其可通过协调对细胞凋亡的抗性而形成肿瘤促进的微环境。使用偶氮甲烷和葡聚糖硫酸钠挑战在P2RY(6)敲除(P2RY(6)( - / - ))小鼠中化学诱导结直肠癌(CRC)。将小鼠安乐死,并确定其肿瘤载荷。针对组织学和免疫组织化学分析染色固定组织。还由从P2RY6(+ / +)小鼠切除的CRC肿瘤制备肿瘤肿瘤,以确定P2Y(6)R在凋亡中的作用,而HT29癌细胞用于阐明P2Y(6)R抗的信号机制-Apoptotic效应。 P2RY(6)( - / - )小鼠产生了减少数量的结肠直肠肿瘤,具有较小的体积的表观肿瘤。 P2RY(6)( - / - )动物的总体发育不良分数显着降低。用选择性激动剂MRS2693刺激P2Y(6)Rs2693受到TNFα-诱导的凋亡的HT-29细胞。该保护效果是通过Akt稳定呼吸蛋白(XIAP)的X型抑制剂的稳定性磷酸化介导的。使用CrC衍生的肿瘤瘤,发现P2Y(6)r活化是有助于化学抑制性,因为添加P2Y(6)r激动剂MRS2693显着阻止了5-氟尿嘧啶的细胞毒性作用。本研究表明,通过阻断凋亡过程并通过促进化学抑制,对CRC患者进行了大量关注,持续激活P2Y(6)R的激活可能会导致肠道肿瘤瘤功能。这些结果表明P2Y(6)R可以代表减少结直肠癌发生的主要靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号